1.   Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS et al.: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984, 311: 819-823.
      2.   Suzuki S, Yoshimura M, Nakayama M, Mizuno Y, Harada E, Ito T et al.: Plasma level of B-type natriuretic peptide as a prognostic marker after acute myocardial infarction: a long-term follow-up analysis. Circulation 2004, 110: 1387-1391.
      3.   Cruden NLM, Witherow FN, Webb DJ, Fox KAA, Newby DE: Bradykinin Contributes to the Systemic Hemodynamic Effects of Chronic Angiotensin-Converting Enzyme Inhibition in Patients With Heart Failure. Arterioscler Thromb Vasc Biol 2004, 24: 1043-1048.
      4.   The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 1999, 353: 9-13.
      5.   Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al.: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341: 709-717.
      6.   Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al.: Eplerenone, a Selective Aldosterone Blocker, in Patients with Left Ventricular Dysfunction after Myocardial Infarction. N Engl J Med 2003, 348: 1309-1321.
      7.   The Heart Outcomes Prevention Evaluation Study Investigators: Effects of an Angiotensin-Converting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients. N Engl J Med 2000, 342: 145-153.
      8.   Daugherty A, Rateri DL, Charo IF, Owens AP, Howatt DA, Cassis LA: Angiotensin II infusion promotes ascending aortic aneurysms: attenuation by CCR2 deficiency in apoE-/- mice. Clin Sci (Lond) 2010, 118: 681-689.
      9.   Tang EH, Shvartz E, Shimizu K, Rocha VZ, Zheng C, Fukuda D et al.: Deletion of EP4 on Bone Marrow-Derived Cells Enhances Inflammation and Angiotensin II-Induced Abdominal Aortic Aneurysm Formation. Arterioscler Thromb Vasc Biol 2010.
    10.   Go AS, Chertow GM, Fan D, McCulloch CE, Hsu Cy: Chronic Kidney Disease and the Risks of Death, Cardiovascular Events, and Hospitalization. N Engl J Med 2004, 351: 1296-1305.
    11.   Siragy HM, Carey RM: Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010, 31: 541-550.
    12.   Jung O, Jansen F, Mieth A, Barbosa-Sicard E, Pliquett RU, Babelova A et al.: Inhibition of the soluble epoxide hydrolase promotes albuminuria in mice with progressive renal disease. PLoS One 2010, 5: e11979.
    13.   Razzaque MS: The dualistic role of vitamin D in vascular calcifications. Kidney Int 2010.
    14.   Ullah MI, Uwaifo GI, Nicholas WC, Koch CA: Does vitamin d deficiency cause hypertension? Current evidence from clinical studies and potential mechanisms. Int J Endocrinol 2010, 2010: 579640.
    15.   Bobryshev YV: Vitamin D3 suppresses immune reactions in atherosclerosis, affecting regulatory T cells and dendritic cell function. Arterioscler Thromb Vasc Biol 2010, 30: 2317-2319.
    16.   Pliquett RU, Fasshauer M, Bluher M, Paschke R: Neurohumoral stimulation in type-2-diabetes as an emerging disease concept. Cardiovasc Diabetol 2004, 3: 4.
    17.   Expert Panel on Detection EaToHBCiA: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001, 285: 2486-2497.
    18.   Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR et al.: The metabolic syndrome. Endocr Rev 2008, 29: 777-822.
    19.   Sattar N, Gaw A, Scherbakova O, Ford I, O'Reilly DS, Haffner SM et al.: Metabolic Syndrome With and Without C-Reactive Protein as a Predictor of Coronary Heart Disease and Diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003, 108: 414-419.
    20.   Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K et al.: General and Abdominal Adiposity and Risk of Death in Europe. New England Journal of Medicine 2008, 359: 2105-2120.
    21.   Lindholm LH, Ibsen H, Borch J, Olsen MH, Wachtell K, Dahlof B et al.: Risk of new-onset diabetes in the Losartan Intervention For Endpoint reduction in hypertension study. J Hypertens 2002, 20: 1879-1886.
    22.   Sabatine MS, Morrow DA, de L, Gibson CM, Murphy SA, Rifai N et al.: Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation 2002, 105: 1760-1763.
    23.   Ridker PM, Macfadyen JG, Nordestgaard BG, Koenig W, Kastelein JJ, Genest J et al.: Rosuvastatin for primary prevention among individuals with elevated high-sensitivity c-reactive protein and 5% to 10% and 10% to 20% 10-year risk. Implications of the Justification for Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial for "intermediate risk". Circ Cardiovasc Qual Outcomes 2010, 3: 447-452.
    24.   : MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360: 23-33.
    25.   Zhang H, Schmeisser A, Garlichs CD, Plotze K, Damme U, Mugge A et al.: Angiotensin II-induced superoxide anion generation in human vascular endothelial cells: role of membrane-bound NADH-/NADPH-oxidases. Cardiovasc Res 1999, 44: 215-222.
    26.   Kukin ML, Kalman J, Charney RH, Levy DK, Buchholz V, Ocampo ON et al.: Prospective, randomized comparison of effect of long-term treatment with metoprolol or carvedilol on symptoms, exercise, ejection fraction, and oxidative stress in heart failure. Circulation 1999, 99: 2645-2651.
    27.   Parizadeh SM, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S et al.: Simvastatin Therapy Reduces Prooxidant-Antioxidant Balance: Results of a Placebo-Controlled Cross-Over Trial. Lipids 2011.
    28.   Ota H, Eto M, Kano MR, Kahyo T, Setou M, Ogawa S et al.: Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol 2010, 30: 2205-2211.
    29.   Vischer UM, Wollheim CB: Epinephrine induces von Willebrand factor release from cultured endothelial cells: involvement of cyclic AMP-dependent signalling in exocytosis. Thromb Haemost 1997, 77: 1182-1188.
    30.   Drummond GR, Cai H, Davis ME, Ramasamy S, Harrison DG: Transcriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression by hydrogen peroxide. Circ Res 2000, 86: 347-354.
    31.   Thomas SR, Chen K, Keaney JF: Hydrogen Peroxide Activates Endothelial Nitric-oxide Synthase through Coordinated Phosphorylation and Dephosphorylation via a Phosphoinositide 3-Kinase-dependent Signaling Pathway. Journal of Biological Chemistry 2002, 277: 6017-6024.
    32.   Aninat C, Seguin P, Descheemaeker PN, Morel F, Malledant Y, Guillouzo A: Catecholamines induce an inflammatory response in human hepatocytes. Crit Care Med 2008, 36: 848-854.
    33.   Schade R, G÷hler K, B³rger W, Hirschelmann R: Modulation of rat C-reactive protein serum level by dexamethasone and adrenaline--comparison with the response of alpha 2-acute phase globulin. Agents Actions 1987, 22: 280-287.
    34.   Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK et al.: betaAR signaling required for diet-induced thermogenesis and obesity resistance. Science 2002, 297: 843-845.
    35.   Aizawa T, Ishizaka N, Usui S, Ohashi N, Ohno M, Nagai R: Angiotensin II and catecholamines increase plasma levels of 8-epi-prostaglandin F(2alpha) with different pressor dependencies in rats. Hypertension 2002, 39: 149-154.
    36.   De L, Terreni L, Sironi M, De S: The sympathetic nervous system tonically inhibits peripheral interleukin-1beta and interleukin-6 induction by central lipopolysaccharide. Neuroscience 1998, 83: 1245-1250.
    37.   Luchner A, Stevens TL, Borgeson DD, Redfield M, Wei CM, Porter JG et al.: Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. Am J Physiol 1998, 274: H1684-H1689.
    38.   Yoshimura M, Yasue H, Morita E, Sakaino N, Jougasaki M, Kurose M et al.: Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991, 84: 1581-1588.
    39.   Yu CM, Sanderson JE: Plasma brain natriuretic peptide--an independent predictor of cardiovascular mortality in acute heart failure. Eur J Heart Fail 1999, 1: 59-65.
    40.   Mukoyama M, Nakao K, Obata K, Jougasaki M, Yoshimura M, Morita E et al.: Augmented secretion of brain natriuretic peptide in acute myocardial infarction. Biochem Biophys Res Commun 1991, 180: 431-436.
    41.   Lam LL, Cameron PA, Schneider HG, Abramson MJ, M³ller C, Krum H: Meta-analysis: effect of B-type natriuretic peptide testing on clinical outcomes in patients with acute dyspnea in the emergency setting. Ann Intern Med 2010, 153: 728-735.
    42.   Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG et al.: N-terminal pro-B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP-Assisted Treatment To Lessen Serial Cardiac Readmissions and Death) trial. J Am Coll Cardiol 2009, 55: 53-60.
    43.   Eurlings LW, van Pol PE, Kok WE, van Wijk S, Lodewijks-van der Bolt C, Balk AH et al.: Management of chronic heart failure guided by individual N-terminal pro-B-type natriuretic peptide targets: results of the PRIMA (Can PRo-brain-natriuretic peptide guided therapy of chronic heart failure IMprove heart fAilure morbidity and mortality?) study. J Am Coll Cardiol 2010, 56: 2090-2100.
    44.   Morita H, Nishida Y, Motochigawa H, Kangawa K, Minamino N, Matsuo H et al.: Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits. Am J Physiol 1989, 256: R792-R796.
    45.   Kambayashi Y, Nakao K, Kimura H, Kawabata T, Nakamura M, Inouye K et al.: Biological characterization of human brain natriuretic peptide (BNP) and rat BNP: species-specific actions of BNP. Biochem Biophys Res Commun 1990, 173: 599-605.
    46.   Ito T, Yoshimura M, Nakamura S, Nakayama M, Shimasaki Y, Harada E et al.: Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes. Circulation 2003, 107: 807-810.
    47.   Cataliotti A, Boerrigter G, Costello-Boerrigter LC, Schirger JA, Tsuruda T, Heublein DM et al.: Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation 2004, 109: 1680-1685.
    48.   Lee SC, Stevens TL, Sandberg SM, Heublein DM, Nelson SM, Jougasaki M et al.: The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail 2002, 8: 149-154.
    49.   Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP: 1,25-Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002, 110: 229-238.
    50.   Huang Y, Noble NA, Zhang J, Xu C, Border WA: Renin-stimulated TGF-[beta]1 expression is regulated by a mitogen-activated protein kinase in mesangial cells. Kidney Int 2007, 72: 45-52.
    51.   Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID S, I: Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008, 358: 2433-2446.
    52.   Phillips LM, Wang Y, Dai T, Feldman DL, Lapage J, Adler SG: The Renin Inhibitor Aliskiren Attenuates High-Glucose Induced Extracellular Matrix Synthesis and Prevents Apoptosis in Cultured Podocytes. Nephron Exp Nephrol 2011, 118: e49-e59.
    53.   Roks AJ, van G, Pinto YM, Buikema H, Henning RH, de Z et al.: Angiotensin-(1-7) is a modulator of the human renin-angiotensin system. Hypertension 1999, 34: 296-301.
    54.   Yamamoto K, Chappell MC, Brosnihan KB, Ferrario CM: In vivo metabolism of angiotensin I by neutral endopeptidase (EC 3.4.24.11) in spontaneously hypertensive rats. Hypertension 1992, 19: 692-696.
    55.   Barton M, Shaw S, Uscio LV, Moreau P, Luscher TF: Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: role of ETA receptors for endothelin regulation. Biochem Biophys Res Commun 1997, 238: 861-865.
    56.   Gao L, Wang WZ, Wang W, Zucker IH: Imbalance of angiotensin type 1 receptor and angiotensin II type 2 receptor in the rostral ventrolateral medulla: potential mechanism for sympathetic overactivity in heart failure. Hypertension 2008, 52: 708-714.
    57.   Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J et al.: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008, 372: 547-553.
    58.   Yoshimura M, Nakamura S, Ito T, Nakayama M, Harada E, Mizuno Y et al.: Expression of aldosterone synthase gene in failing human heart: quantitative analysis using modified real-time polymerase chain reaction. J Clin Endocrinol Metab 2002, 87: 3936-3940.
    59.   Mizuno Y, Yoshimura M, Yasue H, Sakamoto T, Ogawa H, Kugiyama K et al.: Aldosterone production is activated in failing ventricle in humans. Circulation 2001, 103: 72-77.
    60.   Gomez-Sanchez EP, Ahmad N, Romero DG, Gomez-Sanchez CE: Origin of aldosterone in the rat heart. Endocrinology 2004, 145: 4796-4802.
    61.   Linas SL, Peterson LN, Anderson RJ, Aisenbrey GA, Simon FR, Berl T: Mechanism of renal potassium conservation in the rat. Kidney Int 1979, 15: 601-611.
    62.   Bauer JH, Gauntner WC: Effect of potassium chloride on plasma renin activity and plasma aldosterone during sodium restriction in normal man. Kidney Int 1979, 15: 286-293.
    63.   Weber KT: Aldosterone in congestive heart failure. N Engl J Med 2001, 345: 1689-1697.
    64.   Losel RM, Feuring M, Falkenstein E, Wehling M: Nongenomic effects of aldosterone: cellular aspects and clinical implications. Steroids 2002, 67: 493-498.
    65.   Rocha R, Williams GH: Rationale for the use of aldosterone antagonists in congestive heart failure. Drugs 2002, 62: 723-731.
    66.   Hayashi H, Kobara M, Abe M, Tanaka N, Gouda E, Toba H et al.: Aldosterone nongenomically produces NADPH oxidase-dependent reactive oxygen species and induces myocyte apoptosis. Hypertens Res 2008, 31: 363-375.
    67.   Godfrey V, Farquharson CA, Macdonald JE, Yee KM, Struthers AD: Effect of spironolactone on C-reactive protein levels in patients with heart disease. Int J Cardiol 2007, 117: 282-284.
    68.   Funder JW, Mihailidou AS: Aldosterone and mineralocorticoid receptors: Clinical studies and basic biology. Mol Cell Endocrinol 2009, 301: 2-6.
    69.   Liu JL, Pliquett RU, Brewer E, Cornish KG, Shen YT, Zucker IH: Chronic endothelin-1 blockade reduces sympathetic nerve activity in rabbits with heart failure. Am J Physiol Regul Integr Comp Physiol 2001, 280: R1906-R1913.
    70.   Cozza EN, Gomez-Sanchez CE: Mechanisms of ET-1 potentiation of angiotensin II stimulation of aldosterone production. Am J Physiol 1993, 265: E179-E183.
    71.   Browatzki M, Schmidt J, Kubler W, Kranzhofer R: Endothelin-1 induces interleukin-6 release via activation of the transcription factor NF-kappaB in human vascular smooth muscle cells. Basic Res Cardiol 2000, 95: 98-105.
    72.   Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1996, 275: 370-375.
    73.   Hunt BE, Davy KP, Jones PP, DeSouza CA, Van P, Tanaka H et al.: Systemic hemodynamic determinants of blood pressure in women: age, physical activity, and hormone replacement. Am J Physiol 1997, 273: H777-H785.
    74.   Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M et al.: Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 2002, 288: 49-57.
    75.   Writing Group for the Women's Health Initiative Investigators: Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 288: 321-333.
    76.   Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J et al.: Estrogen therapy and coronary-artery calcification. N Engl J Med 2007, 356: 2591-2602.
    77.   Santen RJ, Allred DC, Ardoin SP, Archer DF, Boyd N, Braunstein GD et al.: Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010, 95: s1-s66.
    78.   Singh SK, Goyal R, Pratyush DD: Is hypoandrogenemia a component of metabolic syndrome in males? Exp Clin Endocrinol Diabetes 2011, 119: 30-35.
79.       Ullah MI, Washington T, Kazi M, Tamanna S, Koch CA. Testosterone deficiency as a risk factor for cardiovascular disease. Horm Metab Res 2011
    80.   Bolger AP, Sharma R, Li W, Leenarts M, Kalra PR, Kemp M et al.: Neurohormonal activation and the chronic heart failure syndrome in adults with congenital heart disease. Circulation 2002, 106: 92-99.
    81.   Gao L, Wang W, Li YL, Schultz HD, Liu D, Cornish KG et al.: Superoxide Mediates Sympathoexcitation in Heart Failure: Roles of Angiotensin II and NAD(P)H Oxidase. Circ Res 2004, 95: 937-944.
    82.   Ridker PM, MacFadyen J, Libby P, Glynn RJ: Relation of baseline high-sensitivity C-reactive protein level to cardiovascular outcomes with rosuvastatin in the Justification for Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol 2010, 106: 204-209.
    83.   Heitzer T, Schlinzig T, Krohn K, Meinertz T, Munzel T: Endothelial dysfunction, oxidative stress, and risk of cardiovascular events in patients with coronary artery disease. Circulation 2001, 104: 2673-2678.
    84.   ntuna-Puente B, Feve B, Fellahi S, Bastard JP: Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab 2008, 34: 2-11.
    85.   Kralisch S, Sommer G, Deckert CM, Linke A, Bluher M, Stumvoll M et al.: Adipokines in diabetes and cardiovascular diseases. Minerva Endocrinol 2007, 32: 161-171.
    86.   Rasouli N, Kern PA: Adipocytokines and the metabolic complications of obesity. J Clin Endocrinol Metab 2008, 93: S64-S73.
    87.   Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M et al.: Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002, 106: 2067-2072.